Danaher: Cytiva's Bioprocessing Filtration Portfolio
Former VP of Sales at Pall Corp
inpractise.com/articles/danaher-cytivas-bioprocessing-filtration-portfolio
Danaher: Cytiva's Bioprocessing Filtration Portfolio(March 1, 2024)
Former VP of Sales at Pall Corp
Interview Transcript
This is a snippet of the transcript, sign up to read more.
If it's customized, can you only use Pall consumables? Or can you also use third-party consumables?
The core separation technology, such as the ultrafiltration membranes, could be from any company. It could be from Millipore. It could have been Repligen, or more often than not, it was not Pall. It was mostly Millipore and some Sartorius. Just due to market share, Pall's market share. They had legacy products from the Filtron days. But winning new market share was a struggle for them. They couldn't get it together.
This is a snippet of the transcript, sign up to read more.
Related Content
Danaher, Sartorius, & an Overview of The Bioprocessing Environment
Former VP of Sales at Pall Corp
Pall, Cytiva & the Bioprocessing Manufacturing Process
Former VP of Sales at Pall Corp
Danaher's Pall: Medical vs Biopharma Segment Quality
Former President at Pall
Danaher Business System: Kaizen Case Study at Pall
Former VP of Engineering at Pall, Danaher
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.